Likewise, Zhou et al. showed that pretreatment levels of soluble PD-L1 were also elevated in metastatic melanoma patients when compared to healthy donors; however, it could only be used as a biomarker of progressive disease in a subgroup of patients [29]. Here, CD274 is linked to metastatic melanoma.